ANX Insider Trading Activity and SEC Form 4 Filings
ANX insider trading summary
No open-market insider purchases or sales of Adventrx Pharmaceuticals Inc (ANX) have been reported on SEC Form 4 in the past 12 months.
Latest ANX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 14, 2012 | David A Ramsay | Director | Buy | $27K (50,000 @ $0.54) |
| May 10, 2012 | David A Ramsay | Director | Buy | $23K (40,000 @ $0.57) |
| May 9, 2012 | David A Ramsay | Director | Buy | $6K (10,000 @ $0.55) |
| Mar 14, 2012 | Brian M Culley | CEO and Director | Buy | $12K (20,500 @ $0.59) |
| Mar 13, 2012 | Brian M Culley | CEO and Director | Buy | $8K (14,000 @ $0.58) |
| Dec 16, 2011 | Robert Martin Emanuele | Senior VP, Development | Sell | $24K (41,000 @ $0.60) |
| May 27, 2010 | Brian M Culley | Chief Executive Officer | Buy | $9K (5,000 @ $1.89) |
| May 14, 2008 | Joan M Robbins | CSO, Sr. VP | Buy | $2K (5,000 @ $0.43) |
| May 13, 2008 | Joan M Robbins | CSO, Sr. VP | Buy | $2K (5,000 @ $0.44) |
| Feb 8, 2008 | Evan Levine | CEO & President | Buy | $2K (3,000 @ $0.51) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.